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 Purpose: Coronavirus disease 2019 (COVID-19) has affected millions of people all over 
the world with worse proven outcomes in those with certain comorbid conditions, such as 
diabetes, cardiovascular disease, and pulmonary complications. The Rio Grande Valley located 
in South Texas with a largely Hispanic population has been hit especially hard during this 
pandemic with over 3,200 virus-related deaths. This region’s high population of diabetic and 
obese patients is likely correlated with the especially high mortality rate. While it is understood 
the impact that obesity has on worsening health outcomes, further research is needed to better 
understand whether more adverse COVID-19 outcomes are correlated with an underdiagnosis 
of Obesity Hypoventilation Syndrome (OHS) amongst obese patients.  
 Patients and Methods: Using an observational database from Valley Baptist Medical 
Center (VBMC) in Harlingen, TX, we gathered a list of COVID+ patients admitted between 
March 19, 2020 and September 25, 2020. COVID-19 was diagnosed based on World Health 
Organization (WHO) guidance. The official database is still a work-in-progress, as we are still 
working on manual data-entry for co-existing conditions and lab values for these patients.  
Once the database is completed, evaluation guidelines as listed in the American Journal of 
Respiratory and Critical Care Medicine will be used as a screening method to identify OHS in 
COVID+ patients. COVID-19 outcomes including hospitalization length, ICU transfer/admission, 
intubation count, in-hospital death will then be evaluated.  
 Results: Of the 1114 patients with COVID-19+ included in our database, we have 
completed chart review on 112 patients. Once the database is completed, statistical analysis will 
be performed using Python to see if there is a higher percentage of adverse COVID-19+ 
outcomes in OHS-suspected patients compared to obese patients who don’t meet the criteria 
for OHS. Further analysis will also be done to compare these outcomes to the remaining 
admitted COVID+ patients. 
 Conclusion: Database still in progress and no conclusion can be drawn at this time. 
 
1. Introduction:  
 
 Obesity is correlated with multiple health conditions such as metabolic syndrome, 
hypertension, cardiovascular diseases, pulmonary complications, renal disease, and various 
other obesity-associated comorbidities. These comorbidities place patients in a hypercoagulable 
state and have been shown to correlate with the increased risk of death related to COVID-19 
(1). While there have been a lot of knowledge gained on clinical features of COVID-19 and risk 
factors that places individuals at higher risk for COVID-19 hospitalization, the data is limited 
regarding obesity hypoventilation syndrome (OHS) amongst obese patients and mortality in 
COVID-19. Obesity causes compression of the diaphragm, lungs and chest cavity, which 
increases pulmonary resistance and impairs lung function (2). These patients are at a higher 
risk for a number of pulmonary diseases, such as COPD, asthma, and sleep apnea. Obese 
individuals are also more prone to developing OHS, which presents with additional daytime 
hypoventilation and sleep-disordered breathing (2). Due to the restriction of chest wall 
expansion caused by excessive mass of thoracic tissue present in patients with OHS, these 
patients present with severe upper airway obstruction and restrictive lung damage leading to 
central hypoventilation and impaired compensatory response to acute hypercapnia (2). 
Underdiagnosed and thus untreated OHS could potentially be correlated with worsening 
hypoxemia and cytokine storm in obese patients. Thus, we hypothesize that worse COVID+ 
prognosis in obese patients may be correlated with an underdiagnosis of OHS in this 
population, leading to COVID-19 complications such as acute respiratory distress syndrome 
(ARDS) and multiorgan failure (3).  
Human angiotensin-converting enzyme 2 (ACE2) is the receptor that allows for entry of 
SARS-CoV-2 into target cells (4, 5). The interaction of SARS-CoV-2 with ACE2 receptor, which 
is expressed on several organs including lung, heart, kidney, has been hypothesized to cause 
endothelial damage, leading to tissue damage and cytokine release (6). Furthermore, it is found 
that there is a higher level of ACE2 expression in adipose tissue is much higher than even that 
of lung tissue (4). Obese patients are found to have higher number of ACE2 receptors due to 
increased amount of adipose tissue in these patients (4, 7). This finding coupled with the 
inflammatory disease process, lung injury, and immobility secondary to ICU admission may 
predispose obese individuals to have worse complications with COVID-19 (6). Patients with 
obesity are already in a pro-inflammatory state with an already lower than adequate ventilation 
at baseline. These physiologic disadvantages may facilitate the development of a ‘cytokine 
storm’ when faced with the need to mount off a viral infection. Studies have shown that obesity 
impairs immunity by decreasing the cytotoxic response, reducing the anti-viral role of 
immunocompetent cells (5, 8). The ineffective ability to mount a cellular immune response 
against an infection is likely to be associated with more severe disease outcomes and increased 
mortality in this population of patients with COVID-19 (5).  
Patients with obesity often suffer from a wide variety of other metabolic disorders and 
co-morbidities. The high population of diabetic and obese patients in the Rio Grande Valley is 
likely to be correlated with the high mortality rates of patients with COVID-19 in this region of 
Texas. Thus, in our study we would like to examine further whether there is an underdiagnosis 
of OHS in obese patients and whether those patients suspected of having OHS have more 
severe outcomes of COVID-19. Furthermore, looking at the treatments that these COVID+ and 
OHS-suspected patients have received, we can see whether there are certain treatment 
regimens that fare better than others. This could help us better understand how to approach 




2.1. Data Source 
 
Our study design was guided by a retrospective cohort study on ACEi/ARBs use and 
COVID-19 outcomes (9). We analyzed deidentified data using an automated extraction of data 
from inpatient and outpatient electronic health records at Valley Baptist Medical Center (VBMC) 
in Harlingen, TX. A manual data-entry process was then conducted for verification and 
continued extrapolation of values and risk factors that could not be automatically extrapolated. 
All protected health information was stripped from each record before continuing with manual 
data collection. The collection and analysis of data in the registry have been deemed exempt 
from IRB oversight. 
 
2.2 Patients and eligibility 
 
Our dataset initially included a total of 1566 patients that were automatically extracted 
based on our inclusion criteria of all patients who tested positive with either COVID-19 antigen 
or COVID-19 PCR who presented to Valley Baptist Medical Center between March 19, 2020 
and September 25, 2020. Patients who were still hospitalized past this time frame were still 
included in our study, as the purpose of our study is primarily focused on patient clinical 
characteristics presented at the time of admission. The discharge dates will be edited 
accordingly throughout our manual data-entry process.  
Patients who were admitted to the hospital and were discharged under 24 hours were 
eliminated from our database, as well as patients who passed away from non-COVID related 
health complications. Patients who were infants and under 2 years of age were also excluded 
from our study. After exclusion criteria were met, we were left with 1114 patients to begin our 
manual data-entry process.  
 
2.3. Data Collection 
 
Using COVID reports available from inpatient and outpatient electronic health records at 
VBMC, all patients with COVID-19 antigen (+) or COVID-19 polymerase-chain-reaction (PCR) 
(+) who presented to the hospital between March 19, 2020 and September 15, 2020 were 
recorded. COVID-19 was diagnosed on the basis of the World Health Organization guidance. A 
positive laboratory finding for SARS-CoV-2 was defined as a positive result on nucleic acid 
amplification (NAA) or real-time reverse-transcriptase-PCR (RT-PCR) assay of nasal or 
pharyngeal swab specimens. Patients with a negative test were not included in this study. Only 
one positive test was necessary for the patient to be included in the analysis.  
Patient demographics and clinical information including age, sex, BMI, ethnicity, admit date, 
discharge date were automatically extracted as noted in either inpatient or outpatient electronic 
health record. Coexisting conditions, ACEi/ARBs medications, vital signs, lab values, and 
COVID-19 treatments were manually collected from patient charts. Vital signs and lab values 
are collected within 24-48 hours of presentation to the ER. Vital signs consist of systolic BP, 
diastolic BP, pulse, respiratory rate, temperature, and O2 saturation upon presentation. Lab 
values consist of CO2, CRP, LDH, D-dimer, Ferritin, and CPK from BMP. From the ABG, we will 
also be collecting pCO2, pO2, HCO3-, and pH. Coexisting conditions included history of 
hypertension (HTN), diabetes, smoking history, chronic obstructive pulmonary disease (COPD), 
coronary artery disease (CAD), heart failure (HF), hypothyroidism, and chronic kidney disease 
(CKD). Coexisting conditions were recorded based on patient admission H&P notes, as well as 
under discharge notes for a discharge diagnosis. Use of ACEi/ARBs medication were only 
recorded if they have prescription documented in the EMR and not if they were given the 
medication while in the hospital. If the patient’s EMR did not include information on use of 
ACEi/ARBs or if the patient did not remember medications, this was recorded as not present. 
This was also the case if the EMR designated an unknown smoking history or did not include 
specific coexisting conditions (e.g., hypertension, diabetes, COPD, etc), these were similarly 
recorded as not present. COVID-19 treatment, including administration of steroids, 
anticoagulants, antivirals, or plasma were manually recorded.  
Patient outcomes of this study include total length of hospitalization, admission/transfer 
to ICU during hospitalization, death, endotracheal intubation count, and mechanical ventilation 
count was automatically extracted as well. Of these, only admission/transfer to ICU during 
hospitalization was manually collected.  
 
2.4 Statistical Analysis 
 
The goal of the study is to evaluate whether there is an underdiagnosis of OHS amongst 
patients who are admitted to the hospital and the effect this has on the end point of length of 
hospitalization, ICU admission, need for endotracheal intubation, and hospital death. We plan 
on confounding for demographic characteristics (e.g., age, ethnicity, BMI) as well as coexisting 
conditions. Categorical variables will be shown as frequencies and percentages, and continuous 
variables as means and standard deviations. Independent sample t-tests were completed for all 
comparisons between various categorical and continuous variables. These variables were 
grouped by death, which is one of the outcomes of our study. Further grouping by other 
outcomes including total length of hospitalization, admission/transfer to ICU, endotracheal 
intubation count, and mechanical ventilation count will be included in the future once the 
database is complete. Statistical analysis of this project is still work in progress, as we are still 
waiting to obtain more ABG values in order to see which values are more consistently reported 




We began manual chart review starting from patients admitted June 1st, as this month was 
when the Rio Grande Valley was hit the hardest with the pandemic. Of the 1114 patients with 
COVID-19+ included in our database, we have completed chart review on 112 patients. We 
decided to run a preliminary statistical analysis on these patients to assess our data collection 
methods before we proceed further. The complete database is still work-in-progress. 
Demographic information is summarized in Table 1.  
From the 112 patients that have been charted so far, our population is shown to be 
predominately Hispanic (88.4%) with a disproportionately higher percentage of female patients 
(95.5%) (Table 1). Patient’s BMI and ethnicity were not significantly correlated with COVID-
related mortality (p-value: 0.25 and 0.83, respectively). There was a significant correlation with 
patient’s age in their COVID prognosis with p-value of 0.002. Mean age of COVID-related death 
was 66.6, whereas those that survived had a mean age of 55.6.  
Statistical analysis was then conducted on these patients to find potential correlations with 
co-existing medical conditions on COVID-related mortality. There was a significantly higher 
prevalence of HTN in patients who died from COVID than in patients who survived (80% vs. 
50.6%, p-value: 0.01). Amongst those that passed away from COVID, 70% of these patients 
had history of diabetes, whereas amongst those that survived, 56.8% of those patients had 
history of diabetes. While there is a slight difference amongst these groups, the difference is not 
statistically significant (p-value: 0.30). Furthermore, there was also no significant correlation in 
COVID outcomes amongst patients taking ACEi/ARBs with p-value of 0.23. Statistical analysis 
on the lab values gathered from patient charts were also grouped by death. However, as 
indicated in the third column, there is a significant number of values missing from certain 
patients’ chart. Thus, we will need to continue working on the database to have a larger sample 
size and analysis should be re-conducted on these variables.  
 




Table 1. Our preliminary patient demographics (n= 112) showed a disproportionately higher percentage of female 
patients (95.5%), as well as a largely Hispanic population (88.4%).  
 
  Grouped by DEATH 
  Missing Overall 0.0 1.0 P-Value 
       
n   112 81 31  
GENDER, n (%) 
Female 0 107 (95.5) 78 (96.3) 29 (93.5) 0.616 
Male  5 (4.5) 3 (3.7) 2 (6.5)  
age, mean (SD)  0 58.7 (17.8) 55.6 (17.6) 66.6 (15.9) 0.002 
ETHNICITY, n (%) 
Hispanic 0 99 (88.4) 73 (90.1) 26 (83.9) 0.254 
Non-Hispanic  8 (7.1) 6 (7.4) 2 (6.5)  
Unknown  5 (4.5) 2 (2.5) 3 (9.7)  
BMI, mean (SD)  0 32.8 (10.0) 32.9 (11.2) 32.5 (5.9) 0.826 
Table 2. Co-existing Conditions Grouped by Death 
 
 
Table 2. Patients with history of HTN seemed to be significantly correlated with worse COVID outcomes (p-value 
0.01). No significant correlation noted between use of ACEi/ARBs, history of diabetes, smoking, COPD, CAD, HF, 
hypothyroidism, and CKD on COVID-related mortality. ACEi/ARBs: angiotensin converting enzyme 
inhibitor/angiotensinogen receptor blockers, HTN: hypertension, COPD: chronic obstructive pulmonary disorder, 





















  Grouped by DEATH 
  Missing Overall 0.0 1.0 P-Value 
       
n   112 81 31  
ACEi/ARBs, n (%) 
0.0 1 78 (70.3) 60 (74.1) 18 (60.0) 0.227 
1.0  33 (29.7) 21 (25.9) 12 (40.0)  
HTN, n (%) 
0.0 1 46 (41.4) 40 (49.4) 6 (20.0) 0.010 
1.0  65 (58.6) 41 (50.6) 24 (80.0)  
Diabetes, n (%) 
0.0 1 44 (39.6) 35 (43.2) 9 (30.0) 0.296 
1.0  67 (60.4) 46 (56.8) 21 (70.0)  
Smoking, n (%) 
0.0 1 98 (88.3) 71 (87.7) 27 (90.0) 1.000 
1.0  13 (11.7) 10 (12.3) 3 (10.0)  
COPD, n (%) 
0.0 1 104 (93.7) 76 (93.8) 28 (93.3) 1.000 
1.0  7 (6.3) 5 (6.2) 2 (6.7)  
CAD, n (%) 
0.0 1 97 (87.4) 71 (87.7) 26 (86.7) 1.000 
1.0  14 (12.6) 10 (12.3) 4 (13.3)  
HF, n (%) 
0.0 1 103 (92.8) 76 (93.8) 27 (90.0) 0.444 
1.0  8 (7.2) 5 (6.2) 3 (10.0)  
Hypothyroidism, n (%) 
0.0 1 102 (91.9) 73 (90.1) 29 (96.7) 0.440 
1.0  9 (8.1) 8 (9.9) 1 (3.3)  
CKD, n (%) 
0.0 1 102 (91.9) 74 (91.4) 28 (93.3) 1.000 
1.0  9 (8.1) 7 (8.6) 2 (6.7)  
Table 3. Lab Values Grouped by Death 
 
  
  Grouped by DEATH 
  
  Missing Overall 0.0 1.0 P-Value 
              
n   
  112 81 31   
Serum CO2, mean (SD)   
3 23.4 (5.7) 23.8 (5.0) 22.3 (7.1) 0.295 
CRP, mean (SD)   
73 11.4 (8.3) 10.5 (7.8) 14.0 (9.7) 0.316 
LDH, mean (SD)   
72 339.8 (191.8) 333.5 (204.6) 361.2 (147.2) 0.657 
D-dimer, mean (SD)   
53 102.9 (502.5) 54.3 (190.8) 233.6 (921.7) 0.452 
Ferritin, mean (SD)   
73 34131.5 (209515.9) 609.2 (823.5) 
164030.1 
(462637.9) 0.351 
CPK, mean (SD)   
80 281.1 (487.5) 184.5 (338.1) 493.6 (692.1) 0.207 
pCO2 (from ABG), mean (SD)   
70 33.0 (8.1) 32.9 (8.2) 33.3 (8.2) 0.876 
pCO2 <12.5 (from ABG), n (%) 1.0 
110 2 (100.0) 1 (100.0) 1 (100.0) 1.000 
pO2 (from ABG), mean (SD)   
68 80.1 (41.7) 67.4 (29.6) 102.3 (50.9) 0.020 
HCO3- (from ABG), mean (SD)   
68 19.4 (7.1) 19.5 (6.7) 19.1 (8.0) 0.852 
pH (from ABG), mean (SD)   
68 7.4 (0.1) 7.4 (0.1) 7.3 (0.2) 0.434 
 
Table 3. Higher pO2 from Arterial Blood Gas (ABG) correlated with higher COVID-related mortality (p-value: 0.02). 
However, many lab values were missing as ABG was not ordered in multiple patients. Thus, we will need to perform 
this statistical analysis again after an adequate sample size is obtained.  
 
4. Discussion:  
 
The database for this project is still under works and more patients will need to be reviewed 
before we can decide the most consistent variables to look at in order to predict OHS. 
Potentially, we will base our clinical suspicion for OHS from the evaluation guidelines as listed in 
American Journal of Respiratory and Critical Care Medicine (10). As listed in their summary of 
recommendations on the evaluation and management of OHS, they recommend to measure 
PaCO2 rather than serum bicarbonate or SpO2 to diagnose OHS in obese patients (BMI ≥30 
kg/m2) with sleep-disordered breathing, most likely obstructive sleep apnea (OSA). An elevated 
serum bicarbonate >27 mEq/L could also increase the likelihood of OHS; however, serum 
HCO3- was not found from manual data extraction from any patients. After looking at these 
recommendations, it would retrospectively also be helpful to begin recording history of OSA 
along with our other co-existing clinical conditions. Again, this project thus far is only creating a 
database of COVID+ patients upon admission and an official clinical question is still under 
discussion based on the end result of the database of 1114 patients. The topic on OHS and 
hypothesis that I have based this paper on is one of the discussed hypotheses that could be 
studied once the database is completed. This project that I am hoping to look more into is not 
diagnosing patients with OHS, but instead to find those patients that we have high suspicion for 
OHS in order to see if there is a high underdiagnosis of obesity hypoventilation syndrome in 
patients with worse prognosis of COVID-19 
From the statistical analysis completed on our preliminary dataset, there has been a 
significant correlation shown between patients having history of HTN and COVID-related 
mortality. This finding is consistent with another retrospective study that consisted of 487 
COVID-19 patients in Zhejiang Province of China that showed a higher prevalence of HTN in 
the 49 severe cases of COVID compared to the remaining 439 cases (53.1% vs. 16.7%, p-value 
< 0.0001) (11, 12). Another study in Wuhan, China where the first COVID outbreak began also 
saw a higher prevalence of hypertension amongst patients with more severe COVID-19 cases 
(p-value < 0.001) (13). There is also significant evidence showing multiple other comorbid 
conditions, such as diabetes and coronary artery disease, that are risk factors for more severe 
prognosis of COVID-19. A case series of 5700 patients hospitalized with COVID-19 in the New 
York City area found that patients with diabetes were more likely to have received invasive 
mechanical ventilation or care in the ICU compared to those who did not have diabetes (14). 
The percentage of patients that later developed acute kidney injury as a complication of COVID-
19 was also higher amongst patients with diabetes compared to those without (14). To the 
contrary, our findings as indicated in Table 2 did not show a significant correlation between 
patients having a co-existing condition of diabetes and COVID-related mortality. However, since 
we only grouped these variables by death, we need to also perform statistical analysis grouping 
these co-existing variables by other COVID outcomes, including days of hospitalization, ICU 
admission, endotracheal intubation, and mechanical ventilation. Furthermore, our data may also 
be limited given our smaller sample size. According to Table 2, there also seemed to be no 
correlation found amongst those taking ACEi/ARBs on COVID-related mortality. While initially it 
was thought that these antihypertensive drugs might increase expression of ACE2 and thus 
increase the chance for virus entry into organs, multiple studies have found that ACEi/ARBs do 
not increase risk of COVID-19 requiring ICU admission or fatal cases (11, 15). These studies 
are consistent with our findings thus far. Table 3 in our results showed that there are multiple 
patients that are missing lab values, specifically values gathered from ABG since this was not 
part of COVID protocol when a patient presented to the hospital with a positive COVID test. 
Thus, continued data collection will need to be performed in order to have a higher sample size 
of patients from which we can use the variables to assess for clinical suspicion of OHS.  
The limitations of this study include that this is an observational design, the possibility of 
human manual data-entry error, and the coverage of a short term admission range of ~ 6 
months (March 19, 2020 – September 25, 2020). Another limitation to this study that we noticed 
upon looking at our demographics table is that a majority of our population thus far is female. 
There will need to be a further look into the possible cause for this. Our database also only 
included record of patients who were currently smoking. If there was no documented history of 
smoking or were former smokers, this was recorded as no tobacco use. Current smokers were 
not specified how many pack-years, as this could not be located in the EMR. Since former 
smokers were not reported, this could present many confounding variables, as patients who 
recently smoked >15 pack-years and who recently quit, for example, are likely to carry many of 
the cardiovascular and pulmonary risk factors as current smokers. This flaw in data collection 
may affect the reliability of this variable.  Another confounding variable is if patients were on 
anti-coagulation for other chronic conditions prior to their presentation to the ER. These patients 
may have better COVID-19 outcomes, regardless if they met our criteria for high suspicion for 
OHS. This is based on COVID-19 being a hypercoagulable state and studies showing promising 
evidence in the use of anticoagulation with better prognosis in severe COVID-19 cases as well 
as offer beneficial anti-inflammatory effects to minimize lung damage (16). 
Another limitation of our data collection process is the inclusion of patients who 
presented to the ER with non-COVID related symptoms but rather symptoms of another co-
existing clinical condition. These patients may have been tested prior to undergoing procedure 
for another condition and incidentally tested positive for COVID; however, their initial 
presentation to the ER was not for COVID-related symptoms. Inclusion of these patients may 
bias our population towards less severe COVID-19 prognosis as these patients may be 
asymptomatic for COVID. Furthermore, while we attempted to exclude patients who received 
endotracheal intubation as part of surgery unrelated to COVID-19 related symptoms, there is 
still the possibility of human data-entry error.  
During our data-collection process, we also noticed that some patients who were 
excluded from our study due to being admitted for < 24 hours often times present back to the 
hospital a few days later and were admitted the second time. These patients were excluded 
from our study, but further continuation of this study should include assessment of what 
percentage of COVID+ patients got discharged without admission and presented back again 
with similar or worsening COVID-19 symptoms. Of these patients that presented back a second 
time, we could perform further analysis to see many of these second presentations resulted in 
an admission. As of now, we are still in the process of creating a database for COVID+ admitted 
patients. Thus, future studies will need to take into consideration the data collection limitations 
listed above. Once the database is complete, we hope to further expand our study towards 
better understanding not only the impact of obesity on COVID-19 outcomes, but also look into 
which treatment regimens have better outcomes in this subset of population. More studies need 
to be done to see whether these patients should have a lower threshold for advanced 
respiratory support, intubation or placed on tailored doses of anticoagulation, steroid, or viral 
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